Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 8, 2001, Pages 500-505

  Anderson, Clarke P ^a,b   Seeger, Robert C ^a,b   Satake, Noriko ^a   Monforte Munoz, Hector L ^b   Keshelava, Nino ^a   Bailey, Howard H ^c   Patrick Reynolds, C ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Alkylator resistance; Buthionine sulfoximine; Melphalan; Myeloablative therapy; Neuroblastoma; P glycoprotein

Indexed keywords

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELL SURVIVAL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GLUTATHIONE; HUMANS; MELPHALAN; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

BUTHIONINE SULFOXIMINE; GLUTATHIONE; GLYCOPROTEIN P; MELPHALAN; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TUMOR CELL LINE;

EID: 0035195438     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200111000-00007     Document Type: Article

References (48)

1. Reynolds CP, Seeger RC. Neuroblastoma. In: Haskell CM, ed. Cancer Treatment. Philadelphia: W.B. Saunders, 2000.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N -myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.
3. Haase GM, Perez C, Atkinson JB. Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 1999; 16: 91-104.
4. Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am 1997; 44: 919-37.
5. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21: 181-9.
6. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999; 341: 1165-73.
7. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16: 3053-60.
8. Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant 1997; 20: 543-51.
9. Stram DO, Matthay KK, O’Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children’s Cancer Group studies. J Clin Oncol 1996; 14: 2417-26.
10. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-405.
11. Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer 1997; 33: 2002-6.
12. Tew KD, Houghton PJ, Houghton JA. Modulation of glutathione. In: Tew KD, Houghton PJ, Houghton JA, eds. Preclinical and Clinical Modulation of Anticancer Drugs. Boca Raton, FL: CRC Press, 1993: 13-77.
13. Biaglow JE, Varnes ME, Clark EP, et al. The role of thiols in cellular response to radiation and drugs. Radiat Res 1983; 95: 437-55.
14. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-60.
15. Russo A, DeGraff W, Friedman N, et al. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 1986; 46: 2845-8.
16. Green JA, Vistica DT, Young RC, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44: 5427-31.
17. Hamilton TC, Winker MA, Louie KG, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine-mediated glutathione depletion. Biochem Pharmacol 1985; 34: 2583-6.
18. Siemann DW, Beyers KL. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br J Cancer 1993; 68: 1071-9.
19. Anderson CP, Tsai JM, Meek WE, et al. Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999; 246: 183-92.
20. Anderson CP, Tsai J, Chan W, et al. Buthionine sulfoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Eur J Cancer 1997; 33: 2016-9.
21. Bailey HH, Mulcahy RT, Tutsch KD, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994; 12: 194-205.
22. Ripple GH, Mulcahy RT, Tutsch KD, et al. Tumor glutathione (GSH) depletion to <10% of baseline observed during a phase I trial of continuous infusion L-S, R-buthionine sulfoximine (BSO). Proc Am Assoc Cancer Res 1995; 36: 238.
23. O’Dwyer PJ, Hamilton TC, Young RC, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 1992; 84: 264-7.
24. Yao K, Godwin AK, Ozols RF, et al. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 1993; 53: 3662-6.
25. Anderson CP, Seeger RC, Matthay KK, et al. The combination of buthionine sulfoximine (BSO) and melphalan (L-PAM) is active against recurrent neuroblastoma. Med Pediatr Oncol 1999; 33: 158.
26. Anderson CP, Seeger RC, Matthay KK, et al. Pilot study of buthionine sulfoximine (BSO) and melphalan (L-PAM) in children with recurrent neuroblastoma. Proc Am Soc Clin Oncol 1998; 17: 531.
27. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification. Cancer 1999; 86: 364-72.
28. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-81.
29. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994; 385: 363-9.
30. Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995; 13: 894-901.
31. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12: 2607-13.
32. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 1996; 24: 204-13.
33. Frgala T, Proffit RT, Reynolds CP. A novel 96-well plate cytotoxicity assay based upon fluorescence digital imaging microscopy. Proc Am Assoc Cancer Res 1995; 36: 303.
34. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000; 45: 1-8.
35. Bosanquet AG, Bird MC. Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. Cancer Chemother Pharmacol 1988; 21: 211-5.
36. Chou TC. Dose effect analysis with microcomputers [software program]. Cambridge, MA: Biosoft; 1988.
37. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
38. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977; 252: 6438-42.
39. Chou T. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 1974; 10: 235-47.
40. Vandeputte C. Glutathione. Cell Biol Toxicol 1994; 10: 415-21.
41. Wang YL, Einhorn PA, Triche TJ, et al. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res 2000; 6: 551-8.
42. Reynolds CP, Tomayko MM, Donner L, et al. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res 1988; 271: 291-306.
43. Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with anti-ganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994; 15: 29-37.
44. Keshelava N, Zuo JJ, Luna MC, et al. Loss of p53 function confers multi-drug resistance in neuroblastoma. Med Pediatr Oncol 2000; 35: 563-68.
45. Matthay KK, Atkinson JB, Stram DO, et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children’s Cancer Group pilot study. J Clin Oncol 1993; 11: 2226-33.
46. Lazarus HM, Gray R, Ciobanu N, et al. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Bone Marrow Transplant 1994; 14: 443-8.
47. Pinguet F, Martel P, Fabbro M, et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 605-11.
48. Hersh MR, Ludden TM, Kuhn JG, et al. Pharmacokinetics of high-dose melphalan. Invest New Drugs 1983; 1: 331-4.